 | • レポートコード：MRC2Q12-16948 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療機器＆消耗品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、抗HER2療法のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 抗HER2療法のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 抗HER2療法の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 抗HER2療法のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの抗HER2療法の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の抗HER2療法の売上および2028年までの予測に焦点を当てています。 抗HER2療法のグローバル主要企業には、GlaxoSmithKline、Bayer、Abbott、AbbVie、Pfizer、Sanofi、Merck、Glenmark Pharmaceuticals、Roche、Novartis、Astra Zeneca、Daiichi Sankyo、Celltrion、Teva、Biocon、Viatrisなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 抗HER2療法市場は、タイプとアプリケーションによって区分されます。世界の抗HER2療法市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 抗HER2モノクローナル抗体、抗体医薬品複合体、キナーゼ阻害剤 【アプリケーション別セグメント】 オンライン薬局、小売薬局、診療所 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 抗HER2療法製品概要 - タイプ別市場（抗HER2モノクローナル抗体、抗体医薬品複合体、キナーゼ阻害剤） - アプリケーション別市場（オンライン薬局、小売薬局、診療所） - 調査の目的 ・エグゼクティブサマリー - 世界の抗HER2療法販売量予測2017-2028 - 世界の抗HER2療法売上予測2017-2028 - 抗HER2療法の地域別販売量 - 抗HER2療法の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別抗HER2療法販売量 - 主要メーカー別抗HER2療法売上 - 主要メーカー別抗HER2療法価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（抗HER2モノクローナル抗体、抗体医薬品複合体、キナーゼ阻害剤） - 抗HER2療法のタイプ別販売量 - 抗HER2療法のタイプ別売上 - 抗HER2療法のタイプ別価格 ・アプリケーション別市場規模（オンライン薬局、小売薬局、診療所） - 抗HER2療法のアプリケーション別販売量 - 抗HER2療法のアプリケーション別売上 - 抗HER2療法のアプリケーション別価格 ・北米市場 - 北米の抗HER2療法市場規模（タイプ別、アプリケーション別） - 主要国別の抗HER2療法市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの抗HER2療法市場規模（タイプ別、アプリケーション別） - 主要国別の抗HER2療法市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の抗HER2療法市場規模（タイプ別、アプリケーション別） - 主要国別の抗HER2療法市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の抗HER2療法市場規模（タイプ別、アプリケーション別） - 主要国別の抗HER2療法市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの抗HER2療法市場規模（タイプ別、アプリケーション別） - 主要国別の抗HER2療法市場規模（トルコ、サウジアラビア） ・企業情報 GlaxoSmithKline、Bayer、Abbott、AbbVie、Pfizer、Sanofi、Merck、Glenmark Pharmaceuticals、Roche、Novartis、Astra Zeneca、Daiichi Sankyo、Celltrion、Teva、Biocon、Viatris ・産業チェーン及び販売チャネル分析 - 抗HER2療法の産業チェーン分析 - 抗HER2療法の原材料 - 抗HER2療法の生産プロセス - 抗HER2療法の販売及びマーケティング - 抗HER2療法の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 抗HER2療法の産業動向 - 抗HER2療法のマーケットドライバー - 抗HER2療法の課題 - 抗HER2療法の阻害要因 ・主な調査結果 |
Anti-HER2 Therapy is a class of medicines used to treat all stages of HER2-positive breast cancer and certain HER2-low breast cancers.In HER2-positive breast cancer, the HER2 (human epidermal growth factor receptor 2) gene doesn’t work correctly and makes too many copies of itself. These extra HER2 genes make too many proteins known as HER2 receptors.Anti-HER2 medicines attach to the HER2 receptor proteins on the surface of breast cancer cells.Anti-HER2 medicines work by blocking the HER2 receptors from receiving the growth signals in HER2-positive breast cancer. By blocking the growth signals, anti-HER2 medicines can slow or stop the growth of HER2-positive and HER2-low breast cancer. Anti-HER2 medicines only work on HER2-positive and HER2-low breast cancer. They do not work on HER2-negative breast cancer.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Anti-HER2 Therapy estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Anti-HER2 Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Anti-HER2 Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Anti-HER2 Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Anti-HER2 Therapy include GlaxoSmithKline, Bayer, Abbott, AbbVie, Pfizer, Sanofi, Merck, Glenmark Pharmaceuticals and Roche, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Anti-HER2 Therapy companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Anti-HER2 Therapy market. Further, it explains the major drivers and regional dynamics of the global Anti-HER2 Therapy market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
GlaxoSmithKline
Bayer
Abbott
AbbVie
Pfizer
Sanofi
Merck
Glenmark Pharmaceuticals
Roche
Novartis
Astra Zeneca
Daiichi Sankyo
Celltrion
Teva
Biocon
Viatris
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Anti-HER2 Therapy Segment by Type
Anti-HER2 Monoclonal Antibodies
Antibody-Drug Conjugate
Kinase Inhibitors
Anti-HER2 Therapy Segment by Application
Online Pharmacy
Retail Pharmacy
Medical Clinics
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Anti-HER2 Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Anti-HER2 Therapy market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Anti-HER2 Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Anti-HER2 Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-HER2 Therapy revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Anti-HER2 Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Anti-HER2 Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GlaxoSmithKline, Bayer, Abbott, AbbVie, Pfizer, Sanofi, Merck, Glenmark Pharmaceuticals and Roche, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Anti-HER2 Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-HER2 Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-HER2 Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-HER2 Therapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Anti-HER2 Monoclonal Antibodies
1.2.3 Antibody-Drug Conjugate
1.2.4 Kinase Inhibitors
1.3 Market by Application
1.3.1 Global Anti-HER2 Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Online Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Medical Clinics
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Anti-HER2 Therapy Market Perspective (2017-2028)
2.2 Anti-HER2 Therapy Growth Trends by Region
2.2.1 Anti-HER2 Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Anti-HER2 Therapy Historic Market Size by Region (2017-2022)
2.2.3 Anti-HER2 Therapy Forecasted Market Size by Region (2023-2028)
2.3 Anti-HER2 Therapy Market Dynamics
2.3.1 Anti-HER2 Therapy Industry Trends
2.3.2 Anti-HER2 Therapy Market Drivers
2.3.3 Anti-HER2 Therapy Market Challenges
2.3.4 Anti-HER2 Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-HER2 Therapy Players by Revenue
3.1.1 Global Top Anti-HER2 Therapy Players by Revenue (2017-2022)
3.1.2 Global Anti-HER2 Therapy Revenue Market Share by Players (2017-2022)
3.2 Global Anti-HER2 Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-HER2 Therapy Revenue
3.4 Global Anti-HER2 Therapy Market Concentration Ratio
3.4.1 Global Anti-HER2 Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-HER2 Therapy Revenue in 2021
3.5 Anti-HER2 Therapy Key Players Head office and Area Served
3.6 Key Players Anti-HER2 Therapy Product Solution and Service
3.7 Date of Enter into Anti-HER2 Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-HER2 Therapy Breakdown Data by Type
4.1 Global Anti-HER2 Therapy Historic Market Size by Type (2017-2022)
4.2 Global Anti-HER2 Therapy Forecasted Market Size by Type (2023-2028)
5 Anti-HER2 Therapy Breakdown Data by Application
5.1 Global Anti-HER2 Therapy Historic Market Size by Application (2017-2022)
5.2 Global Anti-HER2 Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Anti-HER2 Therapy Market Size (2017-2028)
6.2 North America Anti-HER2 Therapy Market Size by Type
6.2.1 North America Anti-HER2 Therapy Market Size by Type (2017-2022)
6.2.2 North America Anti-HER2 Therapy Market Size by Type (2023-2028)
6.2.3 North America Anti-HER2 Therapy Market Share by Type (2017-2028)
6.3 North America Anti-HER2 Therapy Market Size by Application
6.3.1 North America Anti-HER2 Therapy Market Size by Application (2017-2022)
6.3.2 North America Anti-HER2 Therapy Market Size by Application (2023-2028)
6.3.3 North America Anti-HER2 Therapy Market Share by Application (2017-2028)
6.4 North America Anti-HER2 Therapy Market Size by Country
6.4.1 North America Anti-HER2 Therapy Market Size by Country (2017-2022)
6.4.2 North America Anti-HER2 Therapy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Anti-HER2 Therapy Market Size (2017-2028)
7.2 Europe Anti-HER2 Therapy Market Size by Type
7.2.1 Europe Anti-HER2 Therapy Market Size by Type (2017-2022)
7.2.2 Europe Anti-HER2 Therapy Market Size by Type (2023-2028)
7.2.3 Europe Anti-HER2 Therapy Market Share by Type (2017-2028)
7.3 Europe Anti-HER2 Therapy Market Size by Application
7.3.1 Europe Anti-HER2 Therapy Market Size by Application (2017-2022)
7.3.2 Europe Anti-HER2 Therapy Market Size by Application (2023-2028)
7.3.3 Europe Anti-HER2 Therapy Market Share by Application (2017-2028)
7.4 Europe Anti-HER2 Therapy Market Size by Country
7.4.1 Europe Anti-HER2 Therapy Market Size by Country (2017-2022)
7.4.2 Europe Anti-HER2 Therapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-HER2 Therapy Market Size (2017-2028)
8.2 Asia-Pacific Anti-HER2 Therapy Market Size by Type
8.2.1 Asia-Pacific Anti-HER2 Therapy Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Anti-HER2 Therapy Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Anti-HER2 Therapy Market Share by Type (2017-2028)
8.3 Asia-Pacific Anti-HER2 Therapy Market Size by Application
8.3.1 Asia-Pacific Anti-HER2 Therapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Anti-HER2 Therapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Anti-HER2 Therapy Market Share by Application (2017-2028)
8.4 Asia-Pacific Anti-HER2 Therapy Market Size by Region
8.4.1 Asia-Pacific Anti-HER2 Therapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Anti-HER2 Therapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Anti-HER2 Therapy Market Size (2017-2028)
9.2 Latin America Anti-HER2 Therapy Market Size by Type
9.2.1 Latin America Anti-HER2 Therapy Market Size by Type (2017-2022)
9.2.2 Latin America Anti-HER2 Therapy Market Size by Type (2023-2028)
9.2.3 Latin America Anti-HER2 Therapy Market Share by Type (2017-2028)
9.3 Latin America Anti-HER2 Therapy Market Size by Application
9.3.1 Latin America Anti-HER2 Therapy Market Size by Application (2017-2022)
9.3.2 Latin America Anti-HER2 Therapy Market Size by Application (2023-2028)
9.3.3 Latin America Anti-HER2 Therapy Market Share by Application (2017-2028)
9.4 Latin America Anti-HER2 Therapy Market Size by Country
9.4.1 Latin America Anti-HER2 Therapy Market Size by Country (2017-2022)
9.4.2 Latin America Anti-HER2 Therapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-HER2 Therapy Market Size (2017-2028)
10.2 Middle East & Africa Anti-HER2 Therapy Market Size by Type
10.2.1 Middle East & Africa Anti-HER2 Therapy Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Anti-HER2 Therapy Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Anti-HER2 Therapy Market Share by Type (2017-2028)
10.3 Middle East & Africa Anti-HER2 Therapy Market Size by Application
10.3.1 Middle East & Africa Anti-HER2 Therapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Anti-HER2 Therapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Anti-HER2 Therapy Market Share by Application (2017-2028)
10.4 Middle East & Africa Anti-HER2 Therapy Market Size by Country
10.4.1 Middle East & Africa Anti-HER2 Therapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Anti-HER2 Therapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Anti-HER2 Therapy Introduction
11.1.4 GlaxoSmithKline Revenue in Anti-HER2 Therapy Business (2017-2022)
11.1.5 GlaxoSmithKline Recent Developments
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Anti-HER2 Therapy Introduction
11.2.4 Bayer Revenue in Anti-HER2 Therapy Business (2017-2022)
11.2.5 Bayer Recent Developments
11.3 Abbott
11.3.1 Abbott Company Details
11.3.2 Abbott Business Overview
11.3.3 Abbott Anti-HER2 Therapy Introduction
11.3.4 Abbott Revenue in Anti-HER2 Therapy Business (2017-2022)
11.3.5 Abbott Recent Developments
11.4 AbbVie
11.4.1 AbbVie Company Details
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Anti-HER2 Therapy Introduction
11.4.4 AbbVie Revenue in Anti-HER2 Therapy Business (2017-2022)
11.4.5 AbbVie Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Anti-HER2 Therapy Introduction
11.5.4 Pfizer Revenue in Anti-HER2 Therapy Business (2017-2022)
11.5.5 Pfizer Recent Developments
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Anti-HER2 Therapy Introduction
11.6.4 Sanofi Revenue in Anti-HER2 Therapy Business (2017-2022)
11.6.5 Sanofi Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Anti-HER2 Therapy Introduction
11.7.4 Merck Revenue in Anti-HER2 Therapy Business (2017-2022)
11.7.5 Merck Recent Developments
11.8 Glenmark Pharmaceuticals
11.8.1 Glenmark Pharmaceuticals Company Details
11.8.2 Glenmark Pharmaceuticals Business Overview
11.8.3 Glenmark Pharmaceuticals Anti-HER2 Therapy Introduction
11.8.4 Glenmark Pharmaceuticals Revenue in Anti-HER2 Therapy Business (2017-2022)
11.8.5 Glenmark Pharmaceuticals Recent Developments
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview
11.9.3 Roche Anti-HER2 Therapy Introduction
11.9.4 Roche Revenue in Anti-HER2 Therapy Business (2017-2022)
11.9.5 Roche Recent Developments
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Anti-HER2 Therapy Introduction
11.10.4 Novartis Revenue in Anti-HER2 Therapy Business (2017-2022)
11.10.5 Novartis Recent Developments
11.11 Astra Zeneca
11.11.1 Astra Zeneca Company Details
11.11.2 Astra Zeneca Business Overview
11.11.3 Astra Zeneca Anti-HER2 Therapy Introduction
11.11.4 Astra Zeneca Revenue in Anti-HER2 Therapy Business (2017-2022)
11.11.5 Astra Zeneca Recent Developments
11.12 Daiichi Sankyo
11.12.1 Daiichi Sankyo Company Details
11.12.2 Daiichi Sankyo Business Overview
11.12.3 Daiichi Sankyo Anti-HER2 Therapy Introduction
11.12.4 Daiichi Sankyo Revenue in Anti-HER2 Therapy Business (2017-2022)
11.12.5 Daiichi Sankyo Recent Developments
11.13 Celltrion
11.13.1 Celltrion Company Details
11.13.2 Celltrion Business Overview
11.13.3 Celltrion Anti-HER2 Therapy Introduction
11.13.4 Celltrion Revenue in Anti-HER2 Therapy Business (2017-2022)
11.13.5 Celltrion Recent Developments
11.14 Teva
11.14.1 Teva Company Details
11.14.2 Teva Business Overview
11.14.3 Teva Anti-HER2 Therapy Introduction
11.14.4 Teva Revenue in Anti-HER2 Therapy Business (2017-2022)
11.14.5 Teva Recent Developments
11.15 Biocon
11.15.1 Biocon Company Details
11.15.2 Biocon Business Overview
11.15.3 Biocon Anti-HER2 Therapy Introduction
11.15.4 Biocon Revenue in Anti-HER2 Therapy Business (2017-2022)
11.15.5 Biocon Recent Developments
11.16 Viatris
11.16.1 Viatris Company Details
11.16.2 Viatris Business Overview
11.16.3 Viatris Anti-HER2 Therapy Introduction
11.16.4 Viatris Revenue in Anti-HER2 Therapy Business (2017-2022)
11.16.5 Viatris Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer